Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have signed a written consent form agreeing to take part
- People who have been diagnosed with relapsed or refractory multiple myeloma or a related plasma cell disease, and whose cancer either did not respond to standard chemotherapy, came back after going into remission, or came back after a stem cell transplant
- People whose cancer cells have been shown to carry a specific protein called BCMA on their surface
- People of any gender aged between 18 and 75 years
- People whose doctors estimate they are expected to live for more than 3 months
- People with a general health/performance score above 60 on the KPS scale (a measure of how well someone is functioning day-to-day — confirm with trial site)
- People with no serious mental health disorders
- People whose heart is pumping at 50% efficiency or more, as measured by a heart scan
- People whose liver is functioning within acceptable limits based on blood tests
- People whose kidneys are functioning within acceptable limits based on blood tests
- People whose blood oxygen levels are 92% or above while breathing normal indoor air
- People who are able to have blood or cells collected without medical contraindications
- People who are willing and able to attend all required trial visits and follow the trial's requirements
Who may not be able to join:
- People who have a history of another type of cancer
- People who have an active infection that is not under control
- People who have a condition that requires ongoing treatment with steroid medications (glucocorticoids)
- People who have active or chronic graft-versus-host disease (GVHD), a complication that can occur after a stem cell transplant
- People who are currently being treated with medications that suppress T cell activity (a type of immune cell)
- People who are pregnant or breastfeeding
- People with other health or personal circumstances that the trial investigators consider unsuitable for participation, such as HIV, hepatitis C infection, or intravenous drug use, or circumstances that may affect the reliability of the trial results
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sanbin Wang, MD, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phone: 86-13206140093
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Adverse events that related to treatment; The response rate of BCMA targeted prime CAR-T treatment in patients with relapse/refractory Multiple Myeloma that treatment by BCMA targeted prime CAR-T cells therapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.